CA-TTTECH-INDUSTRIAL
25.5.2021 10:02:06 CEST | Business Wire | Press release
TTTech Industrial Automation AG has acquired core technology and strategic customers from pioneering fog/edge computing start-up Nebbiolo Technologies in a deal closed in May. Integrating features and know-how from Nebbiolo Technologies will support TTTech Industrial’s commitment to delivering the world’s most advanced industrial edge computing platform to its customers. TTTech Industrial has also founded a US subsidiary in Silicon Valley to expand its activities in the North American market. Kannan Devarajan, one of the co-founders of Nebbiolo Technologies has joined TTTech Industrial North America Inc. as Managing Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005037/en/
TTTech Industrial is a leading provider of industrial IoT solutions, and partners with key players in IoT such as Intel and Microsoft. The company’s Nerve software platform has been at the forefront of industrial edge computing since its launch in 2016. The foundation of TTTech Industrial North America supports the expansion of commercial operations in the US and Canada, with the technology and customer assets acquired from Nebbiolo Technologies forming the nucleus of these activities.
Nebbiolo Technologies is renowned as the pioneer of fog computing, with patented technology that is foundational to industrial edge computing concepts. The company was named a Gartner Cool Vendor in 2017 and was recognized as the Customer Value Leader in the IIoT edge computing market by Frost & Sullivan in 2019. The combination of existing Nerve product features with Nebbiolo Technologies’ expertise will provide customers with an unparalleled solution for software management at the edge, remote connectivity, edge analytics, high-availability, and security.
TTTech Industrial has an existing customer base of machine builders and system integrators based in Europe, the US and Asia. Aside from growing its operations in North America and Asia, this deal also allows TTTech Industrial to widen the scope of its activities to new industries such as energy, oil/gas and auto manufacturing, strengthen the global reach of its edge computing solutions and bolster go-to-market activities in Europe.
"The launch of our US subsidiary marks a significant step for our company. Our location in Silicon Valley brings us closer to customers and allows us to tap into a pool of the world's best software engineering talent. The integration of assets from Nebbiolo Technologies enables us to offer even more advanced industrial edge computing solutions to new and existing customers in a wider range of application fields,” explains Thomas Berndorfer, Member of the Executive Board, TTTech Industrial Automation AG.
“I am very proud to be leading TTTech Industrial's expansion into North America. My team and I bring a wealth of experience in edge computing solutions that will contribute to making Nerve the platform of choice for industrial automation customers. In addition, we will provide customers with expert local sales and technical support, as well as custom feature development," says Kannan Devarajan, Managing Director, TTTech Industrial North America.
CEO and co-founder of Nebbiolo Technologies Chandra Joshi states, “We have been partnering with TTTech Industrial from the outset of our journey. I am confident that the integration of Nebbiolo’s technology with TTTech Industrial’s Nerve product line will create a leading-edge computing platform to enable existing and new customers to accelerate their digital transformation.”
About TTTech Industrial Automation AG
TTTech Industrial aspires to unlock the incredible potential of industrial automation. It combines transformative technologies with hands-on experience in critical real-time systems to offer customers flexibility, reliability and choice. TTTech Industrial operates under the umbrella of the TTTech Group, a leading provider of safe networked computing platforms, with cross-industry experience from more than 20 years of operation.
TTTech Industrial product lines Nerve, Slate and Flexibilis are designed to converge and connect automation systems. Nerve is a flexible, open industrial edge computing platform that enables users to access data, manage devices and deploy applications remotely. Slate is a deterministic networking platform that provides comprehensive TSN solutions. Flexibilis is a redundant networking product portfolio that delivers high-availability seamless redundancy for a wide range of industrial applications, most notably in the energy industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom